drugset / Trial / NCT01311622

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

NCT01311622

Phase 1 Completed 15 enrolled AstraZeneca
Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to determine whether fostamatinib influences the plasma concentration of warfarin and changes its blood thinning effect, and to investigate how safe and tolerable it is when administered with warfarin.

Timeline

Start
2011-03
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 100 mg
Subject Warfarin Small molecule 25 mg

Indications